Limitations of Label-Free Sensors in Serum Based Molecular Diagnostics

Manoj M. Varma^{1,2}

¹Center for Nano Science and Engineering, Indian Institute of Science, Bangalore ²Electrical Communication Engineering, Indian Institute of Science, Bangalore mvarma@cense.iisc.ernet.in

Abstract

Immunoassay formats applicable for clinical or point-of-care diagnostics fall into two broad classes. One which uses labeled secondary antibodies for signal transduction and the other which does not require the use of any labels. Comparison of the limits of detection (LoD) reported by these two sensing approaches over a wide range of detection techniques and target molecules in serum revealed that labeled techniques achieve 2-3 orders of magnitude better LoDs. Further, a vast majority of commercial tests and recent examples of technology translations are based on labeled assay formats. In light of this data, it is argued that extension of traditional labeled approaches and enhancing their functionality may have better clinical impact than the development of newer label-free techniques.

Key words: Immunoassays, point-of-care testing, limits of biomarker detection

Is a "mobile phone revolution" possible in personalized diagnostics?

Ubiquitous access to Information and Communication Technology (ICT), particularly, wireless communication technologies, has radically transformed our lives with mobile-enabled technologies applied in areas ranging from education and entertainment to healthcare [1]. The deep penetration of mobile technologies, even in economically underdeveloped nations, is expected to provide better living conditions through mobile-enabled services in such countries. Analogous to the mobile revolution, we would like to see a radical transformation in human health monitoring enabled by ubiquitous access to affordable personal healthcare devices for continuous monitoring of human health parameters. The health parameters may include macroscopic state variables such as heart rate, ECG (Echocardiogram) and blood pressure as well as microscopic state variables such as the concentration of **biomarker** (text in bold is a glossary item) proteins in serum. One could use the example of ICT to imagine what the key enablers for such a transformation in personal health monitoring would be. Firstly, there should be sensing platforms or techniques where economies of scale can be applied to enable deep global penetration through cost reduction. In the case of ICT, Silicon based integrated electronics technology played this role [1]. In the case of personalized health monitoring it remains to be seen if such a universal platform technology would emerge. Secondly, not only the hardware cost, which is the capital expense, but also the recurring usage cost must be low. In the case of ICT this was possible due to the same economies of scale operating in the Silicon semiconductor manufacturing which led to low unit cost of data usage. In the case of healthcare devices, low usage cost translates to low unit cost of testing in terms of consumables required such as sensors and reagents. Finally, these devices must be easy to use with minimal user intervention required. This is necessary for the widespread adoption of such technology and to encourage its frequent use.

Methods for diagnostic testing: labeled and label-free Immunoassays

Currently health monitoring consists of a few simple tests which are possible at the clinician's office such as blood-pressure or ECG and a large number of tests requiring centralized testing labs causing delays of up to a few days between testing and results [2,3]. As a result, data from continuous monitoring of a given individual over his/her lifespan for parameters even as simple as blood-pressure are not easily available. Such datasets collected over a large

number of individuals over time may reveal as yet undiscovered strategies for disease management or prevention. For several diseases including certain cancers, early detection exponentially improves the survival rate [4]. Even though one may not need day to day or even weekly testing frequency in these cases, there is certainly arguable merit in the development of sensing technologies which could perhaps be used at home and are capable of deep global penetration making early diagnosis accessible across economic strata.

Diagnostic tests are typically done using blood samples and are generally based on the immunoassay format where an antibody or a receptor is bound on a solid surface [5,6, Box 1]. These receptors bind the target biomarker from blood/serum or the sample under consideration. Ambitious goals such as early cancer detection requires the detection of biomarkers present in blood at extremely low concentrations with a high level of specificity using a system with few process steps for ease of use [7, 8]. Two broad classes of biosensors emerge depending on how the binding of target molecules is detected by the sensing instrument. The first class includes gold standards such as ELISA (Enzyme Linked Immunosorbent Assay) where a secondary antibody with a suitable label molecule conjugated to it, binds to the target-receptor complex immobilized on the surface [Box 1]. A better alternative, to enable ease of use, would be to detect the binding of the target molecules to the receptors directly without any secondary antibody labels. This approach is called label-free detection. By eliminating the need for labels and associated sample processing steps, label-free systems can potentially operate with minimal or no user intervention. By combining this simplicity of testing with the ability to detect small concentrations of biomarkers in complex samples such as serum, easy to use label-free sensors hold the promise of radically transforming personalized health diagnostics in a way comparable to the transformation of data communication with the advent of mobile phones.

Box 1: Immunoassay format

The solid phase immunoassay format developed during the 60's and 70's is a method to detect the presence of proteins or other molecules present in a sample using antibodies immobilized on a solid surface such as glass, nitrocellulose or Silicon [9]. As indicated in the figure, antibodies (blue Y shaped objects in the figure) immobilized on the solid surface capture the target molecules (red spheres) from the sample containing other molecules (blue spheres) which may potentially interfere by binding to the antibodies. This is called non-specific binding. The binding of the molecules (target or non-specific molecules) to the solid surface is prevented by appropriately chosen surface blocking steps so that the resultant signal from the sensor is entirely due to the interaction of the sample with the immobilized antibodies. Recently researchers have also developed other ways to capture target molecules, for example aptamers (specific DNA sequences), instead of antibodies. In general, the basic idea of immunoassay is that receptor molecules immobilized on a solid surface capture specific targets from a sample. In any given assay there will be some non-specific component of the signal which needs to be accounted for while interpreting the measurement. There are two broad classes of immunoassays depending on the detection of target receptor binding. One in which a secondary antibody conjugated with a label (blue Y shape with a green star attached to it) is used to bind to the target molecules captured by the immobilized antibodies making a sandwich structure. The signal is read out using properties of the label. For example, the label could be a **fluorophore** which emits light with a certain color or an enzyme molecule which converts a substrate to a colored product as in ELISA tests [10]. This type of detection is referred to as labeled detection. The labeling process and the incubation with secondary antibodies introduce additional process steps as well as increases the usage cost of such tests. As a result, several groups have developed techniques not requiring the use of labeled secondary antibodies. Instead, they may measure the optical refractive index, electrical conductance or mass change associated with the capture of target molecules. Such assays are called label-free assays as they do not use labeled secondary antibodies.



Figure 1 Label-Free and Labeled Immunoassay Schemes

Comparison of limit of detection of labeled and label-free sensors

Label-free sensors have witnessed decades of development with a veritable zoo of techniques available today exploiting physical effects as exotic as superconducting quantum interference [11]. However, in spite of this intense activity, most real-world tests including FDA approved tests are still based on labeled formats such as ELISA and immuno-fluorescence assays [12] and almost all recent examples from literature describing translation of diagnostic technology to real-world applications are also based on the labeled format [2,5-8,13-16]. It is therefore very important now to critically compare the performance of labeled and label-free technologies to understand if there are systematic reasons for the lack of prevalence for label-free technologies. To assess the current state of performance of label-free techniques, I compared the nearly 120 limit of detection (LoD) values reported for label-free and labeled methods for serum based biomarker detection. There were significant differences in the surface functionalization and assay protocols followed by different research groups reporting these LoDs. Consequently such a comparison may suffer from biases arising from the sensitivity of the LoD to the specific experimental protocols. To better compare these two approaches, I identified reports where labeled and label-free assays were performed simultaneously, eliminating any bias arising from differences in experimental protocols. Finally, I also examined recent examples describing translation of sensing techniques into real-world applications. It was found that labeled techniques significantly outperformed label-free techniques in all these contexts. In light of this observation, I argue that extension of traditional labeled assays into lab-on-chip formats and enhancing their performance using innovative signal read-out methods may have a better clinical impact than the frenzied development of newer label-free techniques we have witnessed in recent times.

The LoDs reported by various groups for a range of protein biomarkers, including those related to cancer were examined [17-76]. The complete data set along with the search strings used in the bibliographic database Web of Science [77] for literature survey is provided in Supplmentary Data Table [78]. Only articles reporting LoDs in serum were considered. For each category of data, namely, labeled and label-free, the cumulative distribution function (CDF) [Box 2] of the reported LoD values was constructed. A metric referred here as LoD_{50} was defined based on the CDF. The LoD_{50} is the LoD value for which the CDF function reaches the mid-point. The LoD_{50} value therefore represents a kind of weighted average of the LoDs

reported for each category. There were 54 data points for labeled detection and 53 data points for label-free detection making the comparison reasonable. Further, this comparison was done across proteins ranging from 10 kDa to 600 kDa with assays varying in the antibodies/receptors used, surface functionalization protocols and signal detection methods spanning mechanical, electrical, electrochemical and optical domains involving techniques as wide as Surface Plasmon Resonance, e.g. [41], micro-cantilevers, e.g. [51], fluorescence-immunoassays, e.g. [32], ELISA e.g. [54], optical interferometry, e.g. [25] and Silicon nanowires, e.g. [26]. Therefore, the data collected was a comprehensive representation of serum based labeled and label-free detection approaches. In order to extract the LoD₅₀ value in an objective manner, the data points were fitted with a smooth curve. As seen in Fig. 2 (a), the LoD_{50} value of labeled detection was about 0.1 pM (pico-Molar) while that of label-free detection was around 10 pM indicating a 3 orders of magnitude gap in LoDs in favor of labeled detection methods. An examination of the high performing label-free detection techniques, depicted as "label-free outliers" in Fig. 2 a) revealed that all of them used significant amplification of the signal by using secondary antibodies tagged with micron sized beads, nanoparticles or enzymes. Use of such tagged secondary antibodies is contrary to the label-free detection paradigm and it is debatable whether these techniques should indeed be classified as label-free. Such reports were classified in a new category called "Labelfree secondary amplified" and a reanalysis of the data was done. Out of the 53 data points in the label-free category, 30 of them, i.e. more than 50%, used secondary amplification. The CDF of the different sensing approaches classified into labeled, label-free and label-free secondary amplified is shown in Fig. 2 (b). Understandably, amplification of the label-free signal using secondary antibodies results in an order of magnitude improvement achieving an LoD₅₀ value around 3 pM compared to the LoD₅₀ of about 30 pM for direct label-free detection. However this performance is still nearly two orders of magnitude worse than that achieved by labeled detection which has a LoD_{50} around 0.1 pM.

Box 2: Cumulative Distribution Function

Cumulative Distribution Function (CDF) is a function used in statistics to characterize the distribution of observed values of a variable [79]. CDF curves are generally normalized to a maximum of one so that the range of CDF is always from 0 to 1. The value of a normalized *CDF* curve for a variable V at x, denoted by $CDF_{V}(x)$, represents the probability that a random measurement of V would turn up a value less than x. For e.g. if the CDF for some variable V at x = 100 is 0.05, it means that it is very unlikely for measurements of V to yield values less than 100. We should expect the measurement of V to almost always yield values greater than 100. In the context of this article, CDF(x) represents the probability that a given research article in the respective detection category (labeled or label-free) would report a LoD less than x. For example, the value of CDF curve for label-free detection at LoD of 1 pM is about 0.25 (Figure 2 (a)) while it is about 0.9 for labeled detection. This means that if we picked a random research article dealing with label-free detection there is only a 25% chance that it would report a LoD of less than 1 pM while there is a 90% chance that the reported LoD would be less than 1 pM if the article was dealing with labeled detection. This is the basis for the observation that labeled techniques appear to outperform label-free methods. To construct the approximate CDF curve from a set of observed values, we rank the observations in ascending order and use $CDF(x) = \frac{R(x) - 1}{N - 1}$ where R(x) is the rank (position) of x in the sorted list of observations and N is the total number of observations in the set. We then plot CDF(x) against x for each observed value in the set to obtain the CDF curves shown in Fig. 2 (a) and (b).

To check if there was any correlation between reported LoDs with the molecular mass of the target biomarker, the data was re-plotted in the manner shown in Fig. 2 (c). The horizontal axis is the reported LoD in pM (pico-molar) while the vertical axis is the molecular weight of the target biomarker. Red, green and blue stripes represent labeled, label-free secondary amplified and direct label-free LoDs respectively. We do not see any correlation associated with the different targets considered. In other words the conclusions drawn from Figs. 2 (a) and (b) are valid across the entire range of target biomarkers considered. The conclusion emerging from this analysis is that labeled detection techniques are 2-3 orders of magnitude more sensitive than label-free approaches and it is only after significant signal amplification using tagged secondary antibodies that label-free approaches can attain similar performance.



Figure 2 Analysis of LoDs reported in literature. Fig. 2 (a) shows the CDF [Box1] of labeled (red curve) and label-free (black curve) LoDs. The LoD₅₀, which represents a weighted average, of labeled detection is two orders of magnitude better than that of label-free detection. It was found that label-free techniques which significantly outperformed their peers (depicted as label-free outliers in Fig. 2 (a)) used tagged secondary antibodies for signal amplification. These LoD values were classified in a separate category called label-free secondary amplified ("Label-free Sec Amp" in Fig. 2 (b)) and the CDF curves for the 3 categories were plotted in Fig. 2 (b). Labeled techniques still outperformed label-free techniques in spite of secondary amplification by more than an order of magnitude based on the LoD₅₀ values shown in Fig. 2 (b). Fig. 2 (c) shows that there is no correlation between the achieved LoDs and the molecular weight of the targeted biomarker. Red, green and blue stripes represent labeled, label-free secondary amplified and direct label-free LoDs respectively. Fig. 2 (d) shows the comparison of direct label-free and labeled LoDs measured simultaneously in the same assay eliminating variations arising from

differences in experimental protocols. It is seen that every data point shows better performance

of the labeled technique. The log10 ratio of the label-free to labeled LoD is plotted on the right vertical axis. The mean log10 LoD ratio is around 3 which supports the conclusion from Fig. 2 (a) and (b) that labeled techniques achieve 2-3 orders magnitude better LoDs compared to label-free techniques.

Data from simultaneous labeled and label-free assays

As mentioned earlier, LoD is sensitive to surface functionalization methods and associated experimental protocols. As there are likely to be major variations in these parameters for the data shown in Fig. 2 (a), the best way to compare the two different detection approaches would be to measure the same assay using a labeled and a label-free method simultaneously. Although few in number, some research groups have indeed done such experiments enabling direct comparison of labeled and label-free detection techniques without any confounding factors [24,33,61,72,73]. Fig. 2 (d) plots the label-free LoD on the horizontal axis against the LoD reported for corresponding labeled assay on the left vertical axis. On the right vertical axis the base-10 logarithm of the ratio of label-free LoD to the labeled LoD is plotted. For every single data point in Fig. 2 (d), it is seen that labeled LoD was significantly better than the corresponding label-free LoD. Moreover, the mean log₁₀ ratio of label-free LoD to the labeled LoD of about 3 supports the conclusions drawn from the previous analysis, namely that labeled approaches achieve 2-3 orders of magnitude better LoDs than label-free techniques.

Examination of outlier technologies

It is interesting to examine the best performers in each category to identify techniques that show the highest promise. In the case of labeled detection, Plasmonic ELISA [35] and Digitial ELISA [54] report the best LoDs. In the case of label-free detection, inverse sensitivity assay employing enzyme mediated nanoparticle synthesis [34], massive signal amplification with 1 micron diameter magnetic beads [29], with enzyme conjugated magnetic beads [52] and so on report the best LoDs. However as pointed out earlier, this approach is only superficially different from using fluorophore or enzyme labels as done in labeled immunoassays and it is debatable if they should even be considered as label-free techniques. Direct label-free detection using Si nanowires has reported extremely low LoDs using desalted serum [36]. However, desalting may pose sample pre-treatment challenges. More importantly, such a dramatic performance advantage

of nanowires over other label-free techniques such as SPR, micro-nano-mechanical resonators or even electrochemical methods must really be supported on firm theoretical grounds which is currently lacking. To summarize, the analysis of LoDs reported in serum strongly suggests that secondary antibody labels are required to achieve performance compared to traditional labeled techniques such as ELISA or fluorescence immunoassays. However, amplification using tagged secondary antibodies runs contrary to the label-free detection paradigm of direct detection with minimal sample processing and perhaps such approaches shouldn't even be considered as labelfree.

Why might label-free assays perform worse than labeled assays?

Secondary antibody amplified label-free LoD₅₀ is still at least an order of magnitude worse than the LoD₅₀ of labeled approach even though both approaches use labels. Ignoring multiplicative factors, LoD can be written as $LoD = \frac{\sigma_{noise}}{S}$ where σ_{noise} is the noise floor of measurement and S is the sensitivity of the measurement technique [80]. It is believed that the noise floor in the current generation of biosensors mostly arises from non-specific binding (NSB) processes, for e.g., binding of interfering molecules to the receptors [81]. In this case, the noise floor will be the standard deviation of signal produced by a negative control sample, which in the case of serum based tests will be serum devoid of the target biomarker. In the case of labeled techniques, $\sigma_{\scriptscriptstyle noise}$ mainly arises from NSB of the secondary antibody to the target biomarker or unblocked sensor surface. However, in the case of label-free approaches, irrespective of whether they are amplified or not, σ_{noise} can arise due to the NSB of the secondary antibody, NSB of the target biomarker, erosion of receptors [67] or similar phenomena related to the functionalization layers. In other words the noise floor of label-free detection is likely to be larger than that of labeled approaches. The improvement in LoD₅₀ for secondary antibody tagged amplified labelfree sensors arises from increased sensitivity (larger S) due to signal amplification. This is a plausible model to explain the observations in Fig. 2.

Conclusions and implications for clinical assay development

Perhaps related to the observations made above, examination of commercial tests for FDA approved serum biomarkers [12] or the list of recent examples demonstrating the translation of

biosensing techniques from lab to the real world [2,5-8,13-16], we see that almost all of them are based on labeled assay formats with color based or fluorescence readouts. It is impossible to find even a single example in this domain which uses a sophisticated label-free technique such as nanowires or nano-mechanical resonators. On the other hand many of these technology translations employ clever variations of the labeled detection strategies. In this regard, recent extensions of conventional labeled detection techniques such as Digital-ELISA [55], Plasmonic-ELISA [35], inverse sensitivity assay [34] and so on, show great promise. In light of these observations, I argue that extension of traditional labeled assays into lab-on-chip formats and enhancing their performance using innovative signal read-out methods may have a better clinical impact than the continued development of newer label-free techniques leading to a highly fragmented techno-commerical landscape unlike the dominant Silicon semiconductor platform technology which formed the basis for the digital revolution. Digital-ELISA and Plasmonic-ELISA are notable recent examples in this direction. However, this is not to suggest that labelfree techniques serve no purpose. There are several applications involving detection of molecules in simple samples such as buffers, or those involving large molecules or markers that appear in large concentration, where label-free techniques may indeed leverage their simplicity and cost advantages. However, when the requirement is to measure ultra-low (sub pM) concentration of markers from a complex sample such as serum, it appears that labeled detection strategies currently have a significant performance advantage over label-free techniques. It is hoped that the data presented here will stimulate discussions leading to a critical and realistic assessment of the capabilities of label-free techniques and help identify applications where their unique strengths can be exploited.

References

- 1. Fehske, A. et al. (2011) The Global Footprint of Mobile Communications: The Ecological and Economic Perspective *IEEE Communications Magazine* 49, 55-62
- Drain, P. K. et al. (2014) Diagnostic point-of-care tests in resource-limited settings Lancet Infect Dis. 14, 239–249
- 3. Park, S. et al. (2014) Toward Integrated Molecular Diagnostic System (iMDx): Principles and Applications *IEEE Trans. Biomed. Engg*, 61, 1506-1521

- Konforte, D. and Diamandis, E. P. (2013) Is Early Detection of Cancer with Circulating Biomarkers Feasible? *Clinical Chemistry* 59 35–37
- 5. Cretich, M. et al. (2014) Protein microarray technology: how far off is routine diagnostics? *Analyst* 139, 528-542
- 6. Sin, M. L. et al. (2014) Advances and challenges in biosensor-based diagnosis of infectious diseases *Expert Rev. Mol. Diagn* 14, 225-244
- 7. Woolley, C. F. and Hayes, M. A. (2013) Recent developments in emerging microimmunoassays *Bioanalysis* 5, 245–264
- 8. Song, Y. et al. (2014) Point-of-care technologies for molecular diagnostics using a drop of blood *Trends in Biotech*. 32, 132-139
- 9. Mikkelsen, S. R. and Corton, E. (2004) *Bioanalytical Chemistry* John Wiley and Sons, Hoboken, New Jersey
- 10. Lequin, R. M. (2005) Enzyme Immunoassay (EIA)/Enzyme-Linked Immunosorbent Assay (ELISA) *Clinical Chemistry* 51, 2415–2418
- 11. Uchida S. et al. (2014) Highly Sensitive Liquid-Phase Detection of Biological TargetsWith Magnetic Markers and High Tc SQUID *IEEE Trans. Applied Supercond.* 24 1600105
- Anderson N. L. (2010) The Clinical Plasma Proteome: A Survey of Clinical Assays for Proteins in Plasma and Serum *Clinical Chemistry* 56, 177–185
- 13. Chin, C. D. et al. (2012) Commercialization of microfluidic point-of-care diagnostic devices *Lab Chip* 12, 2118–2134
- Dixit C. K. (2013) Biochips Based In vitro Diagnostics: Market Trends and Research J Biochips Tiss Chips 3, e124
- 15. Chin, C. D. et al. (2011) Microfluidics-based diagnostics of infectious diseases in the developing world *Nature Medicine*, 17, 1015-1020
- 16. Laksanasopin, T. et al. (2015) A smartphone dongle for diagnosis of infectious diseases at the point of care *Science Trans. Med.* 7, 273re1
- Nam, J. M. et al. (2003) Nanoparticle-Based Bio–Bar Codes for the Ultrasensitive Detection of Proteins *Science* 301, 1884-1886
- 18. Yu, F. et al. (2004) Surface Plasmon Fluorescence Immunoassay of Free Prostate-Specific Antigen in Human Plasma at the Femtomolar Level *Anal. Chem.* 76, 6765-6770

- Battaglia, T. M. et al. (2005) Quantification of Cytokines Involved in Wound Healing Using Surface Plasmon Resonance Anal. Chem. 77, 7016-7023
- 20. Liu, M. Y. et al. (2005) Multiplexed Analysis of Biomarkers Related to Obesity and the Metabolic Syndrome in Human Plasma, Using the Luminex-100 System *Clinical Chemistry* 51, 1102–1109
- 21. Zheng, G. et al. (2005) Multiplexed electrical detection of cancer markers with nanowire sensor arrays *Nature Biotechnology* 23, 1294-1301
- 22. Waggoner, P. S. et al. (2009) Detection of prostate specific antigen with nanomechanical resonators *Lab Chip* 9, 3095–3099
- 23. Chowdhury, F. et al. (2009) Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling *Journal of Immunological Methods* 340, 55–64
- 24. Wang, Y. et al. (2009) Prostate Specific Antigen Biosensor Based on Long Range Surface Plasmon-Enhanced Fluorescence Spectroscopy and Dextran Hydrogel Binding Matrix Anal. Chem. 81, 9625–9632
- 25. Wang, X. et al. (2011) Prostate specific antigen detection in patient sera by fluorescencefree BioCD protein array *Biosensors and Bioelectronics* 26, 1871–1875
- 26. Kim, A. et al. (2010) Direct label-free electrical immunodetection in human serum using a flow-through-apparatus approach with integrated field-effect transistors *Biosensors and Bioelectronics* 25, 1767–1773
- 27. Fu, Q. et al. (2010) Comparison of Multiplex Immunoassay Platforms *Clinical Chemistry* 56, 314–318
- 28. Uluda, Y. et al. (2010) Development of a sensitive detection method of cancer biomarkers in human serum (75%) using a quartz crystal microbalance sensor and nanoparticles amplification system *Talanta* 82, 277–282
- 29. Krishnan, S. et al. (2011) Attomolar Detection of a Cancer Biomarker Protein in Serum by Surface Plasmon Resonance Using Superparamagnetic Particle Labels *Angew. Chem. Int. Ed.* 50, 1175–1178
- Shultz, M. A. et al. (2013) Optimized Blocking Of Porous Nitrocellulose Films For Sensitive Protein Microarrays *BioTechniques* 54, 223–225

- 31. Dabitao, D. et al. (2011) Multiplex measurement of proinflammatory cytokines in human serum: comparison of the Meso Scale Discovery electrochemiluminescence assay and the Cytometric Bead Array *J Immunol Methods*. 372, 71–77
- 32. Breen, E. C. et al (2011) Multisite Comparison of High-Sensitivity Multiplex Cytokine Assays *Clinical and Vaccine Immunology* 18, 1229–1242
- 33. Yuk, J. S. et al. (2012) Analysis of immunoarrays using a gold grating-based dual mode surface plasmon-coupled emission (SPCE) sensor chip *Analyst* 137, 2574–2581
- 34. Rodríguez-Lorenzo, L. et al. (2012) Plasmonic nanosensors with inverse sensitivity by means of enzyme-guided crystal growth *Nature Materials* 11, 604-607
- 35. de la Rica, R. et al. (2012) Plasmonic ELISA for the ultrasensitive detection of disease biomarkers with the naked eye *Nature Nanotechnology* 7, 821-824
- 36. Huang, YW. et al. (2013) Real-Time and Label-Free Detection of the Prostate-Specific Antigen in Human Serum by a Polycrystalline Silicon Nanowire Field-Effect Transistor Biosensor Anal. Chem. 85, 7912–7918
- 37. Lee, SW. et al. (2013) Improved porous silicon microarray based prostate specific antigen immunoassay by optimized surface density of the capture antibody *Analytica Chimica Acta* 796, 108–114
- Kyprianou D. et al. (2013) Development of optical immunosensors for detection of proteins in serum *Talanta* 103, 260–266
- 39. Vaisocherova, H. et al. (2009) Comparative study of SPR and ELISA methods based on analysis of CD166/ALCAM levels in cancer and control human sera *Biosensors and Bioelectronics* 24, 2143–2148
- 40. Brault, N. D. et al. (2010) Ultra-low fouling and functionalizable zwitterionic coatings grafted onto SiO2 via a biomimetic adhesive group for sensing and detection in complex media *Biosensors and Bioelectronics* 25, 2276–2282
- 41. Piliarik, M. et al. (2010) Surface plasmon resonance biosensor for parallelized detection of protein biomarkers in diluted blood plasma *Biosensors and Bioelectronics* 26, 1656–1661
- 42. von Muhlen, M. G. (2010) Label-Free Biomarker Sensing in Undiluted Serum with Suspended Microchannel Resonators *Anal. Chem.* 82, 1905–1910

- 43. Zhang, B. et al. (2007) A novel multi-array immunoassay device for tumor markers based on insert-plug model of piezoelectric immunosensor *Biosens. and Bioelec.* 23, 19–25
- 44. Bangar, M. A. et al. (2009) Single Conducting Polymer Nanowire Chemiresistive Label-Free Immunosensor for Cancer Biomarker *Anal. Chem.* 81, 2168–2175
- 45. Das, J. et al (2011) Protein Detection Using Arrayed Microsensor Chips: Tuning Sensor Footprint to Achieve Ultrasensitive Readout of CA-125 in Serum and Whole Blood Anal. Chem. 83, 1167–1172
- 46. Huckabay, H. A. et al (2013) Label-free detection of ovarian cancer biomarkers using whispering gallery mode imaging *Biosensors and Bioelectronics*, 45, 223–229
- 47. Sennikov, S. V. et al. (2003) Quantitative analysis of human immunoregulatory cytokines by electrochemiluminescence method *J. of Immunol Methods* 275, 81–88
- 48. DuPont N. C. et al. (2005) Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: Determinations of a panel of nine cytokines in clinical sample culture supernatants *Journal of Reproductive Immunology* 66, 175–191
- Luchansky, M. S. and Bailey, R. C. (2011) Rapid, Multiparameter Profiling of Cellular Secretion Using Silicon Photonic Microring Resonator Arrays J. Am. Chem. Soc. 133, 20500–20506
- 50. Sauer, U. et al. (2011) Protein chip for the parallel quantification of high and low abundant biomarkers for sepsis *Analytical Biochemistry* 419, 46–52
- 51. Joo, J. et al. (2012) Highly Sensitive Diagnostic Assay for the Detection of Protein Biomarkers Using Microresonators and Multifunctional Nanoparticles ACS Nano 6, 4375–4381
- Malhotra, R. et al. (2012) Ultrasensitive Detection of Cancer Biomarkers in the Clinic by Use of a Nanostructured Microfluidic Array *Anal. Chem.* 84, 6249–6255
- 53. Kindt, J. T. et al. (2013) Subpicogram Per Milliliter Detection of Interleukins Using Silicon Photonic Microring Resonators and an Enzymatic Signal Enhancement Strategy *Anal. Chem.* 85, 10653–10657
- 54. Rissin, D. M. et al. (2013) Multiplexed single molecule immunoassays *Lab Chip*, 13, 2902–2911
- 55. Zhang, B. et al. (2013) Multiplexed cytokine detection on plasmonic gold substrates with enhanced near-infrared fluorescence *Nano Research* 6, 113–120

- 56. Stigter, E.C.A. et. al (2005) An improved coating for the isolation and quantitation of interferon-gamma in spiked plasma using surface plasmon resonance (SPR) *Biosensors* and *Bioelectronics* 21, 474–482
- 57. Liu, Y. et al. (2010) Aptamer-Based Electrochemical Biosensor for Interferon Gamma Detection Anal. Chem. 2010, 82, 8131–8136
- 58. Sipova, H. et al. (2012) Surface plasmon resonance biosensor based on engineered proteins for direct detection of interferon-gamma in diluted blood plasma Sens. and Act. B 174, 306–311
- 59. Zhao, J. et al. (2012) An electrochemical aptasensor based on hybridization chain reaction with enzyme-signal amplification for interferon-gamma detection *Biosensors* and *Bioelectronics* 36, 129–134
- 60. Jiang, J. et al. (2013) A homogeneous hemin/G-quadruplex DNAzyme based turn-on chemiluminescence aptasensor for interferon-gamma detection via in-situ assembly of luminol functionalized gold nanoparticles, deoxyribonucleic acid, interferon-gamma and hemin *Analytica Chimica Acta* 791, 60– 64
- 61. Wang, X. et al. (2008) Area-scaling of interferometric and fluorescent detection of protein on antibody microarrays *Biosensors and Bioelectronics* 24, 981–987
- 62. Bornhop, D. J. et al. (2007) Free-Solution, Label-Free Molecular Interactions Studied by Back-Scattering Interferometry *Science* 317, 1732-1736
- Luchansky, M. S. and Bailey, R. C. (2010) Silicon Photonic Microring Resonators for Quantitative Cytokine Detection and T-Cell Secretion Analysis *Anal. Chem.* 82, 1975– 1981
- 64. Messina, G. M. et al. (2008) Microfluidic immunosensor design for the quantification of interleukin-6 in human serum samples *Analytical Biochemistry* 380, 262–267
- 65. Chou, TH. et al. (2010) Quantification of Interleukin-6 in cell culture medium using surface plasmon resonance biosensors *Cytokine* 51, 107–111
- 66. Li, Y. et al. (2010) Nanomagnetic Competition Assay for Low-Abundance Protein Biomarker Quantification in Unprocessed Human Sera J. Am. Chem. Soc. 132, 4388– 4392
- 67. Ahn, S. et al. (2013) A Mass-Tagging Approach for Enhanced Sensitivity of Dynamic Cytokine Detection Using a Label-Free Biosensor *Langmuir* 29, 5369–5376

- 68. Lee, S. et al. (2013) Gold-nanopatterned single interleukin-6 sandwich immunoassay chips with zeptomolar detection capability based on evanescent field-enhanced fluorescence imaging *Analyst* 138, 3478–3482
- Yang, CY. et al. (2005) Detection of picomolar levels of interleukin-8 in human saliva by SPR Lab Chip 5, 1017–1023
- 70. Waggoner, P. S. et al. (2010) Microfluidic integration of nanomechanical resonators for protein analysis in serum *Sensors and Actuators B* 150, 550–555
- 71. Wan, Y. et al. (2011) Carbon nanotube-based ultrasensitive multiplexing electrochemical immunosensor for cancer biomarkers *Biosens. and Bioelectron.* 30, 93–99
- 72. Livache, T. et al. (2003) Polypyrrole based DNA hybridization assays: study of label free detection processes versus fluorescence on microchips *Journal of Pharmaceutical and Biomedical Analysis* 32, 687-696
- 73. Glass, T. R. et al. (2007) Least Detectable Concentration and Dynamic Range of Three Immunoassay Systems Using the Same Antibody, *Anal. Chem.* 79, 1954-1960
- 74. Sigma Aldrich product information page for RAB0013, retrieved 15-02-2015 http://www.sigmaaldrich.com/catalog/product/sigma/rab0013?lang=en®ion=IN
- 75. Human Luminex Screening Assay information page, retrieved 15-02-2015 http://www.rndsystems.com/Products/LXSAH
- 76. Product data sheet for Abcam product PSA (KLK3) Human ELISA Kit ab113327, retrieved 15-02-2015 <u>http://www.abcam.com/PSA-KLK3nbspHuman-ELISA-Kit-ab113327.pdf</u>
- 77. https://webofknowledge.com from Thomson Reuters
- 78. Supplementaty MS Excel data file accompanying this article
- 79. Kreyszig, E. (2007) Advanced Engineering Mathematics, 8th Ed. Chap. 22, Wiley India, New Delhi
- Wilson, R. (2013) Sensitivity and specificity: twin goals of proteomics assays. Can they be combined? *Expert Rev. Proteomics* 10, 135–149
- Arlett, J. L. (2011) Comparative advantages of mechanical biosensors Nature Nanotech
 6, 203-215

Glossary Items

Biomarkers: Biomarkers are molecules whose concentration in serum could indicate a diseased condition or predict the imminent development of disease. For e.g. elevated serum concentration of a protein called Prostate Specific Antigen (PSA) could indicate the presence of prostate cancer.

ELISA: Enzyme Linked Immunosorbent Assay (ELISA) is a commonly used immunoassay format where an enzyme labelled secondary antibody is used to bind targets captured by primary antibodies immobilized on a solid surface. Signal detection is based on the color change produced by the action of the enzyme on molecules referred to as substrate.

Fluorophore: A fluorophore is a molecule which can absorb light around a peak absorption wavelength and emit light at slightly longer wavelengths. They can be used for labelling secondary antibodies in labelled immunoassays.

Immunoassay: Immunoassay is the term used to describe the method to test for the presence of a molecule of interest, referred to as the target, using another molecule having a specific affinity for the target, such as an antibody against the target.

LoD: Limit of Detection (LoD) is the smallest concentration of targeted molecule that can be detected by a sensing technique. It is directly proportional to the ratio of noise floor of measurement and the sensitivity.

Sensitivity: Sensitivity of a sensor is the slope of the signal response to the stimulus. In the case of biosensors, it is the signal response per unit change in the concentration of the target molecule.

Serum: Serum is the fraction of blood without the cells and clotting factor. It contains several potential biomarkers.

	This is tl	he sunnle	ementary	data table for	the article Limita	tions of Lab	el-Free S	ensors	
	in Serur	n Based	Molecula	r Diagnostics;	Manoj M. Varma	. The table	below she	ows the	
	limit of	detectior	n (LoD) co	ollected for sev	eral label-free (LF) and labele	ed immun	oassay	
	method	s. Label-1	free dete	ction is further	classified into LF	direct and I	F sec am	p. "LF	
	sec amp	" refers t	to the use	e of tagged sec	ondary antibodies	s for signal a	amplificat	tion.	
	strings u	used for a	collecting	this data are g	iven in the next sl	heet.	The search	11	
Mole cule	Molec ular weigh t (Mw) in Literat ure	Mw Assu med (kDa)	Detec tion Categ ory	Technique	Sample Type	LoD (From Ref)	LoD (ng/m L)	LoD (pM)	Refere nce
PSA	~ 30 kDa	30	Labele d	FL (Fluorescen ce)	goat serum	1 fg/mL	0.000 001	3.33E -05	17
PSA	~ 30 kDa	30	Labele d	SPR (Surface Plasmon Resonance) enhanced FL	female human plasma	2 pg/mL	0.002	6.67E -02	18
IL-1 (a/b)	17 kDa	17	LF direct	Fiber Optic SPR	4% bovine serum	1 ng/mL	1	5.88E +01	19
IL-6	23.7 kDa	23.7	LF direct	Fiber Optic SPR	CCM (Cell Culture Media) with 4% FBS (Fetal Bovine Serum)	1 ng/mL	1	4.22E +01	19
TNF-a	~ 17 kDa	17	LF direct	Fiber Optic SPR	CCM with 10% FBS	1 ng/mL	1	5.88E +01	19
IL-6	23.7 kDa	23.7	Labele d	Luminex	pooled human plasma	0.75 pg/mL	0.000 75	3.16E -02	20
IL-6	23.7 kDa	23.7	Labele d	ELISA	pooled human plasma	70 fg/mL	0.000 07	2.95E -03	20
IL-8	~ 10 kDa	10	Labele d	Luminex (Bead FL)	pooled human plasma	1.3 pg/mL	0.001 3	1.30E -01	20
IL-8	~ 10 kDa	10	Labele d	ELISA	pooled human plasma	0.26 pg/mL	0.000 26	2.60E -02	20

PSA	~ 30 kDa	30	LF direct	Si NW	desalted donkey serum	1 pg/mL	0.001	3.33E -02	21
PSA	~ 30 kDa	30	LF sec amp	Si cantilever	fetal bovine serum	50 fg/mL	0.000 05	1.67E -03	22
IFN-g	17 - 19 KDa	18	Labele d	MSD (Meso Scale Discovery)	spiked human plasma	0.7 pg/mL	0.000 7	3.89E -02	23
IL-2	15.3 kDa	15.3	Labele d	Luminex	spiked human plasma	8.7 pg/mL	0.008 7	5.69E -01	23
IL-2	15.3 kDa	15.3	Labele d	MSD	spiked human plasma	2.5 pg/mL	0.002 5	1.63E -01	23
IL-4	15 kDa	15	Labele d	Luminex	spiked human plasma	8.6 pg/mL	0.008 6	5.73E -01	23
IL-4	15 kDa	15	Labele d	MSD	spiked human plasma	0.7 pg/mL	0.000 7	4.67E -02	23
IL-8	~ 10 kDa	10	Labele d	Luminex	spiked human plasma	7.7 pg/mL	0.007 7	7.70E -01	23
IL-8	~ 10 kDa	10	Labele d	MSD	spiked human plasma	0.7 pg/mL	0.000 7	7.00E -02	23
TNF-a	~ 17 kDa	17	Labele d	Luminex	spiked human plasma	6 pg/mL	0.006	3.53E -01	23
TNF-a	~ 17 kDa	17	Labele d	MSD	spiked human plasma	3 pg/mL	0.003	1.76E -01	23
PSA	~ 30 kDa	30	Labele d	SPR enh FL	human serum	10 pg/mL	0.01	3.33E -01	24
PSA	~ 30 kDa	30	LF direct	SPR	human serum	10 ng/mL	10	3.33E +02	24
PSA	~ 30 kDa	30	LF sec amp	Reflectance	human serum	4 ng/mL	4	1.33E +02	25
PSA	~ 30 kDa	30	LF direct	Si nanowire	native human serum	10 ng/mL	10	3.33E +02	26
IL-1 (a/b)	17 kDa	17	Labele d	Luminex, MSD etc	human serum	~ 1pg/mL	0.001	5.88E -02	27
IL-2	15.3 kDa	15.3	Labele d	Luminex	spiked human serum	2.1 pg/mL	0.002 1	1.37E -01	27
IL-6	23.7 kDa	23.7	Labele d	Luminex	human serum	0.6 pg/mL	0.000 6	2.53E -02	27
PSA	~ 30 kDa	30	LF sec amp	QCM (Quartz Crystal Microbalan ce)	75% human serum	300 pg/mL	0.3	1.00E +01	28

I	PSA	~ 30	30	LF sec	SPR	calf serum	10	0.000	3.33E	29
		kDa		amp			fg/mL	01	-04	
	PSA	~ 30	30	LF sec	SPR	calf serum	10	0.01	3.33E	29
		kDa		amp			pg/mL		-01	
	IL-1	17 kDa	17	Labele	FL	human serum	12	0.012	7.06E	30
	(a/b)			d			pg/mL		-01	
	IL-6	23.7	23.7	Labele	FL	spiked human	4.3	0.004	1.81E	30
		kDa		d		serum	pg/mL	3	-01	
	TNF-2	~ 17	17	Labele	FI	sniked human	5 ng/ml	0.005	2 Q/F	30
	ini a	kDa	17	d		serum	5 pg/mL	0.005	_01	50
		КDa		u		scrum			01	
	IL-6	23.7	23.7	Labele	Luminex	human serum	1.6	0.001	6.75E	31
		kDa		d			pg/mL	6	-02	
	IL-6	23.7	23.7	Labele	MSD	human serum	1 pg/mL	0.001	4.22E	31
		kDa		d					-02	
	IL-8	~ 10	10	Labele	Luminex	human serum	4 pg/mL	0.004	4.00E	31
		kDa		d					-01	
	IL-8	~ 10	10	Labele	MSD	human serum	0.2	0.000	2.00E	31
		kDa		d			pg/mL	2	-02	
	IFN-g	17 - 19	18	Labele	Luminex	human Serum	1 pg/mL	0.001	5.56E	32
		KDa		d					-02	
	IL-2	15.3	15.3	Labele	Luminex	spiked human	1.1	0.001	7.19E	32
		kDa		d		serum	pg/mL	1	-02	
		4510	4.5				10,	0.000	4 9 9 5	
	IL-4	15 kDa	15	Labele	Luminex	spiked human	0.6	0.000	4.00E	32
				a		serum	pg/mL	6	-02	
ľ	IL-5	15.2	15.2	Labele	Luminex	spiked human	2.7	0.002	1.78E	32
		kDa		d		serum	pg/mL	7	-01	
	11-6	23.7	23.7	Lahele	Luminex	sniked human	4.6	0.004	1 94F	32
		kDa	25.7	d	Lummex	serum	ng/ml	6	-01	52
		КРU		ŭ		scrum	P6/112	Ŭ	01	
	IL-8	~ 10	10	Labele	Luminex	spiked human	1 pg/mL	0.001	1.00E	32
		kDa		d		serum			-01	
ľ	TNF-a	~ 17	17	Labele	Luminex	spiked human	600	0.000	3.53E	32
		kDa		d		serum	fg/mL	6	-02	
	-		47		600	1 ((0.		5 005	22
	INF-a	~ 1/	1/		SPR	buffer	1 ng/mL	1	5.88E	33
	-	kDa	47	direct		1 ((10	0.04	+01	22
	INF-a	~ 1/	17	Labele	SP coupled	buffer	10	0.01	5.88E	33
		кра	47	a	FL	h 6 f =	pg/mL	0.1	-01	22
	пин-а	- 1/	1/	Lapele	ELISA	butter	100	0.1	5.88E	33
	DCA	кра	20	0			pg/mL	45.00	+00	24
	P2A	~ 30 kDe	30	LF SEC	LSPK	numan serum		1E-09	3.33E	34
		кра		amp			attog/m		-08	
		~ 20	20			human corum	L 1	15.00	2 225	25
	гэА	50 100	30	LF Sec	LOPK	numan serum	L attor/m	TE-09	3.33E	35
		кDd		amp		1	allog/III		-00	

						L			
PSA	~ 30 kDa	30	LF direct	Si nanowire	human serum	5 fg/mL (dubiou s)	0.000 005	1.67E -04	36
PSA	~ 30 kDa	30	Labele d	FL	human serum	0.8 pg/mL	0.000 8	2.67E -02	37
PSA	~ 30 kDa	30	LF sec amp	SPR	20% human serum	5 ng/mL	5	1.67E +02	38
ALCA M	65 kDa	65	LF direct	SPR	10% human serum	20 ng/mL	20	3.08E +02	39
ALCA M	65 kDa	65	Labele d	ELISA	human serum	0.1 ng/mL	0.1	1.54E +00	39
ALCA M	65 kDa	65	LF direct	SPR	human serum	64 ng/mL	64	9.85E +02	40
ALCA M	65 kDa	65	LF direct	imaging SPR	10% human plasma	45 ng/mL	45	6.92E +02	41
ALCA M	65 kDa	65	LF direct	Suspended microchann el resonator (SMR)	undiluted fetal bovine serum	10 ng/mL	10	1.54E +02	42
CA12 5	0.2 - 1 MDa	600	LF direct	QCM	human serum/plasma	5 U/mL	5	8.33E +00	43
CA12 5	0.2 - 1 MDa	600	LF direct	Electrical impedance	human plasma	1 U/mL	1	1.67E +00	44
CA12 5	0.2 - 1 MDa	600	LF direct	Electroche mical	human serum	0.1 U/mL	0.1	1.67E -01	45
CA12 5	0.2 - 1 MDa	600	LF direct	Optical cavity	human serum	1.8 U/mL	1.8	3.00E +00	46
IL-2	15.3 kDa	15.3	Labele d	Electroche miluminesc ence	human serum	1 pg/mL	0.001	6.54E -02	47
IL-4	15 kDa	15	LF sec amp	Electroche milum	human serum	2 pg/mL	0.002	1.33E -01	47
TNF-a	~ 17 kDa	17	Labele d	Bead FL	human serum	3 pg/mL	0.003	1.76E -01	48
TNF-a	~ 17 kDa	17	Labele d	ELISA	human serum	5 pg/mL	0.005	2.94E -01	48
IL-2	15.3 kDa	15.3	LF sec amp	MRR (micro-ring resonator)	CCM with 10% FBS	1.9 ng/mL	1.9	1.24E +02	49
IL-4	15 kDa	15	LF sec amp	MRR	CCM with 10% FBS	1 ng/mL	1	6.67E +01	49
IL-5	15.2 kDa	15.2	LF sec amp	MRR	CCM with 10% FBS	3.4 ng/mL	3.4	2.24E +02	49

TNF-a	~ 17 kDa	17	LF sec amp	MRR	CCM with 10% FBS	4.6 ng/mL	4.6	2.71E +02	49
IL-8	~ 10 kDa	10	Labele d	FL	human serum	26 pg/mL	0.026	2.60E +00	50
IL-6	23.7 kDa	23.7	LF sec amp	Si cantilever	human serum	100 fg/mL	0.000 1	4.22E -03	51
IL-6	23.7 kDa	23.7	LF sec amp	Electroche mical	calf serum	10 fg/mL	0.000 01	4.22E -04	52
IL-8	~ 10 kDa	10	LF sec amp	Electroche mical	calf serum	10 fg/mL	0.000 01	1.00E -03	52
IL-2	15.3 kDa	15.3	LF sec amp	MRR	CCM with 10% FBS	~ 10 pg/mL	0.01	6.54E -01	53
IL-6	23.7 kDa	23.7	LF sec amp	MRR	CCM with 10% FBS	~ 10 pg/mL	0.01	4.22E -01	53
IL-8	~ 10 kDa	10	LF sec amp	MRR	CCM with 10% FBS	~ 10 pg/mL (check)	0.01	1.00E +00	53
IL-1 (a/b)	17 kDa	17	Labele d	ELISA	bovine serum	30 fg/mL	0.000 03	1.76E -03	54
IL-6	23.7 kDa	23.7	Labele d	Digital ELISA	spiked bovine serum	24 fg/mL	0.000 024	1.01E -03	54
TNF-a	~ 17 kDa	17	Labele d	Digital ELISA	human serum	70 fg/mL	0.000 07	4.12E -03	54
IFN-g	17 - 19 KDa	18	Labele d	FL	human serum	6 pg/mL	0.006	3.33E -01	55
IFN-g	17 - 19 KDa	18	Labele d	Plas Enh NIR FL	10% fetal bovine serum	250 fg/mL	0.000 25	1.39E -02	55
IL-1 (a/b)	17 kDa	17	Labele d	Plas Enh NIR FL	10% fetal bovne serum	70 fg/mL	0.000 07	4.12E -03	55
IL-4	15 kDa	15	Labele d	Plas Enh NIR FL	10% fetal bovne serum	1.3 pg/mL	0.001 3	8.67E -02	55
IL-6	23.7 kDa	23.7	Labele d	Plas Enh NIR FL	10% fetal bovne serum	60 fg/mL	0.000 06	2.53E -03	55
TNF-a	~ 17 kDa	17	Labele d	Plas Enh NIR FL	10% fetal bovne serum	470 fg/mL	0.000 47	2.76E -02	55
IFN-g	17 - 19 KDa	18	LF direct	SPR	100x diluted bovine serum	250 ng/mL	250	1.39E +04	56
IFN-g	17 - 19 KDa	18	LF direct	Electroche mical	RPMI/10% fetal bovine serum	5 ng/mL	5	2.78E +02	57

IFN-g	17 - 19 KDa	18	LF direct	SPR	2% depleted human plasma	10 ng/mL	10	5.56E +02	58
IFN-g	17 - 19 KDa	18	LF sec amp	Electroche mical	fetal bovine serum	200 ng/mL	200	1.11E +04	59
IFN-g	17 - 19 KDa	18	LF direct	Chemilumin escence	5% human serum	20 ng/mL	20	1.11E +03	60
Rabbi t IgG	150 kDa	150	Labele d	BioCD (Interferom etry)	bovine serum	30 pg/mL	0.03	2.00E -01	61
Rabbi t IgG	150 kDa	150	LF direct	BioCD	bovine serum	250 pg/mL	0.25	1.67E +00	61
Rabbi t IgG	150 kDa	150	LF sec amp	BioCD	bovine serum	70 pg/mL	0.07	4.67E -01	61
IL-2	15.3 kDa	15.3	LF Direct	BSI (Backscatte ring Interferome try)	media containing 1% serum	150 pg/mL	0.15	9.80E +00	62
IL-2	15.3 kDa	15.3	LF sec amp	MRR	CCM with 10% FBS	1 ng/mL	1	6.54E +01	63
IL-8	~ 10 kDa	10	LF sec amp	MRR	CCM with 10% FBS	1 ng/mL	1	1.00E +02	63
IL-6	23.7 kDa	23.7	LF sec amp	Electroche mical	serum	410 fg/mL	0.000 41	1.73E -02	64
IL-6	23.7 kDa	23.7	LF sec amp	SPR	CCM with 10% FBS	2 ng/mL	2	8.44E +01	65
IL-6	23.7 kDa	23.7	LF direct	SPR	CCM with 10% FBS	> 12 ng/mL	12	5.06E +02	65
IL-6	23.7 kDa	23.7	LF sec amp	GMR (Giant Magneto- resistance)	serum	9 pg/mL	0.009	3.80E -01	66
IL-6	23.7 kDa	23.7	LF direct	Reflectance	buffer	19 ng/mL	19	8.02E +02	67
IL-6	23.7 kDa	23.7	LF sec amp	Reflectance	buffer	2 ng/mL	2	8.44E +01	67
IL-6	23.7 kDa	23.7	Labele d	Nano Enh FL	buffer and serum	12.9 attog/m L	1.3E- 08	5.49E -07	68
IL-8	~ 10 kDa	10	LF sec amp	SPR	human saliva	2.2 ng/mL	2.2	2.20E +02	69
PSA	~ 30 kDa	30	LF sec amp	Si cantilever	human serum	30 fg/mL	0.000 03	1.00E -03	70

PSA	~ 30 kDa	30	LF sec amp	Electroche mical	100% human serum	1 ng/mL	1	3.33E +01	71
PSA	~ 30 kDa	30	LF sec amp	Electroche mical	10% human serum	0.1 ng/mL	0.1	3.33E +00	71
ssDN A (25bp)	8.2 kDa	8.2	LF direct	imaging SPR	Buffer	10 nM		1.00E +04	72
ssDN A (25bp)	8.2 kDa	8.2	LF direct	QCM	Buffer	250 nM		2.50E +05	72
ssDN A (25bp)	8.2 kDa	8.2	Labele d	FL	Buffer	1 - 10 pM		5.00E +00	72
Estrad iol	272 Da	0.272	Labele d	ELISA	Buffer; 4 diff Abs in 3 diff sensing methods	7.3 nM		7.30E +03	73
Estrad iol	272 Da	0.272	LF direct	SPR	Buffer	20 nM		2.00E +04	73
Estrad iol	272 Da	0.272	Labele d	FL	Buffer	40 pM		4.00E +01	73
Estrad iol	272 Da	0.272	Labele d	ELISA	Buffer	0.3 nM		3.00E +02	73
Estrad iol	272 Da	0.272	LF direct	SPR	Buffer	20 nM		2.00E +04	73
Estrad iol	272 Da	0.272	Labele d	FL	Buffer	2 pico M		2.00E +00	73
Estrad	272 Da	0.272	Labele	ELISA	Buffer	0.6 nM		6.00E +02	73
Estrad	272 Da	0.272	LF direct	SPR	Buffer	49 nM		4.90E +04	73
Estrad	272 Da	0.272	Labele	FL	Buffer	20 pM		2.00E +01	73
Estrad	272 Da	0.272	Labele	ELISA	Buffer	0.3 nM		3.00E	73
Estrad	272	0.272	LF	SPR	Buffer	4.3 nM		4.30E	73
Estrad	272	0.272	Labele	FL	Buffer	2 pico M		+03 2.00E	73
iol ALCA	Da 65 kDa	65	d Labele	ELISA	diluted serum	0.03	0.03	+00 4.62E	74
M CA12	0.2 - 1	600	d Labele	Luminex	human serum	ng/mL 2.7	0.02	-01 3.33E	75
5	MDa		d			pg/mL		-02	

PSA	~ 30	30	Labele	ELISA	human serum	10	0.01	3.33E	76
	kDa		d			pg/mL		-01	

Search Strings Used

Technique	Technology Variant	Search String
Labeled	Fluorescence/ELISA	(ts = sens* OR ts = assay) AND (ti = fluor* OR ti = ELISA) AND
		(ts = analyte)
Label-free (LF)	All	(ts = sens* OR ts = assay) AND (ts = "label free" OR ts =
generic		label-free) AND (ts = analyte)
Limit of	All	(ts = "limit of detection") AND (ts = analyte)
detection		
LF Optical	SPR	(ts = sens* OR ts = assay) AND (ts = SPR OR ts = plasmon*)
		AND (ts = analyte)
	Optical cavities,	(ts = sens* OR ts = assay) AND (ts = silicon OR ts = resona*)
	Micro-ring resonators	AND (ts = analyte)
	Interferometry	(ts = sens* OR ts = assay) AND (ts = interfer*) AND (ts =
		analyte)
	General Optical	(ts = sens* OR ts = assay) AND (ts = optic*) AND (ts =
		analyte)
	Reflectance	(ts = sens* OR ts = assay) AND (ts = reflect*) AND (ts =
		analyte)
LF Electrical	Nanowire	(ts = sens* OR ts = assay) AND (ts = silicon OR ts = nanowire
		OR ts = nano-wire OR ts = CNT OR ts = nano-tube) AND (ts =
		analyte)
	Impedance	(ts = sens* OR ts = assay) AND (ts = imped*) AND (ts =
		analyte)
LF Mass/mech	cantilever	(ts = sens* OR ts = assay) AND (ts = cantilever OR ts = MEMS
		OR ts = silicon OR ts = micro-mech* OR ts = micromech* OR
		ts = resona*) AND (ts = analyte)
	QCM	(ts = sens* OR ts = assay) AND (ts = QCM OR ts = "quartz
		crystal") AND (ts = analyte)
LF Electrochem	Electrochemical	(ts = sens* OR ts = assay) AND (ts = electroche*) AND (ts =
		analyte)
LF magnetic		(ts = sens* OR ts = assay) AND (ts = *magnet*) AND (ts =
		analyte)
		The term "analyte" in the search strings above was
		substituted with the appropriate biomarker, e.g. PSA, IL6
		and so on for each category listed above